Summary: Managing insomnia in people who also have obstructive sleep apnea (OSA)—a condition often called COMISA (comorbid insomnia and sleep apnea)—requires careful balancing. Sedative-hypnotic medications can help patients fall and stay asleep, but clinicians have long worried they might relax airway muscles too much, worsening apneas and lowering blood oxygen levels.
A comprehensive systematic review and network meta-analysis examined 32 randomized controlled trials to determine which hypnotics improve sleep architecture while preserving respiratory safety in adults with OSA.
Key Facts
- No general respiratory harm for most hypnotics: The analysis found no consistent evidence that most modern hypnotics significantly worsened respiratory outcomes. Core measures such as the Apnea–Hypopnea Index (AHI) were generally similar to placebo for the majority of drugs assessed.
- Temazepam was an exception: The benzodiazepine temazepam was associated with reduced arterial oxygen saturation during sleep, indicating a higher respiratory risk for patients with OSA.
- Individualized treatment matters: Researchers stress choosing medications based on the patient’s specific insomnia pattern—difficulty falling asleep versus difficulty staying asleep—to maximize benefit and minimize risk.
- Results include CPAP users and non-users: The study considered patients both with and without continuous positive airway pressure (CPAP) use, making findings relevant to those who cannot tolerate or are not using CPAP therapy.
- First comprehensive network comparison: This is the first network meta-analysis to compare multiple hypnotics across both sleep quality and respiratory safety outcomes in adults with OSA.
Source: Fujita Health University
Background: Obstructive sleep apnea is a common sleep disorder marked by repeated airway collapse during sleep that causes oxygen desaturation and sleep fragmentation. OSA is linked to metabolic and cardiovascular problems and reduces quality of life. Insomnia symptoms frequently co-occur with OSA (COMISA), complicating standard approaches such as CPAP, which remains the recommended treatment for moderate to severe OSA but can be poorly tolerated by some patients.
While clinical guidelines favor cognitive behavioral therapy for insomnia (CBT-I) in people with OSA, sedative-hypnotic medications are commonly used in clinical practice. Concern persists that some hypnotics may worsen breathing during sleep, which prompted this systematic review and network meta-analysis.
Researchers from Fujita Health University in Japan, led by Professor Taro Kishi (Department of Psychiatry), conducted the review to identify hypnotics that optimize sleep architecture without compromising respiratory safety. The team included Tsuyoshi Kitajima, Nakao Iwata, Kenji Sakuma, and other collaborators from the same department.
The full study was published online on February 10, 2026, in the journal Psychiatry and Clinical Neurosciences.
“Hypnotic agents differ in how they affect both sleep quality and breathing during sleep,” says Prof. Kishi. “Our goal was to provide evidence to support safer, more symptom-specific medication choices for patients with OSA.”
The network meta-analysis included 32 randomized controlled trials (total n = 1,871; mean age ≈ 51.6 years; about 62.5% male; mean AHI ≈ 23.6) and compared 12 hypnotic agents plus placebo: brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, and zopiclone.
Seventeen outcomes were assessed and grouped into categories: sleep architecture (total sleep time, REM sleep time, sleep efficiency, latency to persistent sleep, wake after sleep onset), respiratory function (AHI during total sleep time, AHI by sleep stage, mean peripheral oxygen saturation, SpO2 nadir, arousal index), treatment acceptability and tolerability (discontinuation rates), and adverse events.
Results showed that hypnotics varied in their effects on sleep. Lemborexant notably increased total sleep time (TST), REM sleep time and sleep efficiency, while reducing latency to persistent sleep and wake after sleep onset. Daridorexant and zolpidem also increased TST and sleep efficiency and reduced wake after sleep onset. Importantly, those three medications demonstrated respiratory safety and discontinuation profiles comparable to placebo.
Eszopiclone produced improvements in TST and sleep efficiency and reduced latency to sleep, wake after sleep onset, AHI during total sleep time, and arousal index; however, some of these effects were not sustained in sensitivity analyses that excluded CPAP titration studies.
Overall, the analysis did not find broad, consistent evidence that hypnotics worsen respiratory outcomes in OSA patients. The notable exception was temazepam, which was associated with decreased arterial oxygen saturation during sleep and therefore may carry a greater risk in this population. Clinicians should individualize treatment, carefully weigh benefits versus risks, and monitor respiratory status when prescribing hypnotics to patients with OSA.
“Because our analysis included both CPAP users and non-users, we also conducted sensitivity analyses excluding CPAP titration studies to ensure the findings are relevant for patients who are not using positive airway pressure therapy,” adds Dr. Kenji Sakuma.
Key Questions Answered:
A: According to this extensive analysis of 12 different drugs, most modern hypnotics did not show a general worsening of respiratory measures. That suggests many options can be used safely under medical supervision, but treatment must be individualized and monitored.
A: The study highlighted temazepam because it was linked to lower oxygen saturation during sleep. Patients and clinicians should avoid assuming all sleep aids are interchangeable and should select drugs based on the insomnia pattern and respiratory risk.
A: CPAP remains the gold standard because it treats the underlying airway collapse, not just insomnia symptoms. Hypnotics address sleep difficulties but do not prevent airway obstruction. For patients who cannot tolerate CPAP, however, some hypnotics may offer a reasonable alternative to help restore sleep while minimizing respiratory harm.
Editorial Notes:
- This article was edited by an editorial team.
- The journal paper was reviewed in full by staff.
- Additional context and clarification were added by the editorial team.
About this OSA and neuropharmacology research news
Author: Hisatsugu Koshimizu
Source: Fujita Health University
Contact: Hisatsugu Koshimizu – Fujita Health University
Image: The image is credited to Neuroscience News
Original Research: Open access. Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis by Taro Kishi MD, PhD; Toshikazu Ikuta PhD; Kenji Sakuma MD, PhD; Masakazu Hatano PhD; Tatsuhiko Kishi MD; Tsuyoshi Kitajima MD, PhD; Nakao Iwata MD, PhD. DOI: 10.1111/pcn.70036
Abstract
Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis
Aim
This network meta-analysis of randomized controlled trials aimed to determine which hypnotic agents are associated with the most favorable sleep architecture and respiratory outcomes in adults with obstructive sleep apnea.
Methods
Primary outcomes included total sleep time (TST) and apnea–hypopnea index (AHI) during TST. Secondary measures examined REM sleep time, latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), AHI by sleep stage, mean peripheral oxygen saturation (SpO2) during TST, SpO2 nadir during TST, arousal index (AI), all-cause discontinuation, adverse event–related discontinuation, and incidence of specific adverse events. Effect sizes and 95% confidence intervals were calculated for each outcome.
Results
The review included 32 RCTs (n = 1,871; average age ≈ 51.6 years; 62.5% male; mean AHI ≈ 23.6). The network meta-analysis compared brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo. Lemborexant increased TST, REM sleep time, and SE and reduced LPS and WASO compared with placebo. Daridorexant and zolpidem also increased TST and SE and reduced WASO. These three demonstrated respiratory safety and discontinuation rates similar to placebo. Eszopiclone improved several sleep metrics and reduced AHI during TST and AI, but some effects did not persist in sensitivity analyses that excluded CPAP titration studies.
Conclusion
Different hypnotic agents exert varied effects on sleep architecture and respiratory parameters in adults with OSA. Although most agents did not show clear respiratory harm, temazepam was associated with reduced oxygen saturation and warrants caution. Limitations in available data prevented a full synthesis of subjective outcomes; therefore, clinicians should interpret these results carefully and tailor treatment to individual patients.
Funding information
This research was supported by JSPS KAKENHI Grant Number 25K10874 (Grant-in-Aid for Scientific Research (C)).